Joshua Schechter
Joshua Schechter's purchase track record
How the stock did after each of Joshua Schechter's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/10/2025 | PRSU | $34K | +10.6% | +22.7% | +8.5% |
| 5/9/2023 | PRSU | $44K | +34.3% | +33.6% | +6.3% |
| 1/12/2022 | LFCR | $104K | -0.6% | -4.0% | -19.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
PRSU Sets Date for Q3 2026 Earnings Release. Pursuit Attractions and Hospitality Inc. (PRSU) has announced the date for its third quarter 2026 earnings release and conference call. The company will report results on the scheduled date, giving investors a chance to review financial performance. The announcement comes as the stock shows a high relative strength index and a recent volume spike, indicating active trading interest. The information is useful for tracking the company’s upcoming financial update.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Barnwell Sells Canadian Oil Unit, Ends Pension Plan. Barnwell Industries is divesting its Canadian oil and natural gas business for C$9 million. The company also announced the termination of its pension plan and the planned return of surplus assets to shareholders. These moves shift the company's asset structure and cash flow profile.
Transaction History
| LFCR | ▲ Buy | Grant | 25,907 | — | 6/4/2026 | View on chart |
| PRSU | ▲ Buy | Grant | 3,596 | $0 | 3/1/2026 | View on chart |
| BRN | ▲ Buy | Grant | 43,860 | — | 12/3/2025 | View on chart |
| PRSU | ▲ Buy | Open Market | 1,000 | $34K | 11/10/2025 | View on chart |
| LFCR | ▲ Buy | Grant | 19,506 | — | 7/15/2025 | View on chart |
| PRSU | ▲ Buy | Grant | 3,149 | $0 | 3/1/2025 | View on chart |
| LFCR | ▲ Buy | Grant | 30,000 | — | 7/8/2024 | View on chart |
| PRSU | ▲ Buy | Grant | 3,376 | $0 | 3/1/2024 | View on chart |
| LFCR | ▲ Buy | Option Exercise | 9,554 | — | 2/1/2024 | View on chart |
| LFCR | ▲ Buy | Grant | 18,182 | — | 6/1/2023 | View on chart |
| LFCR | ▲ Buy | Option Exercise | 9,474 | — | 5/31/2023 | View on chart |
| PRSU | ▲ Buy | Open Market | 1,000 | $22K | 5/9/2023 | View on chart |
| PRSU | ▲ Buy | Open Market | 1,000 | $22K | 5/9/2023 | View on chart |
| PRSU | ▲ Buy | Grant | 4,980 | $0 | 3/1/2023 | View on chart |
| LFCR | ▲ Buy | Grant | 7,059 | $67K | 6/4/2022 | View on chart |
| PRSU | ▲ Buy | Grant | 3,681 | $0 | 2/23/2022 | View on chart |
| LFCR | ▲ Buy | Open Market | 8,000 | $83K | 1/12/2022 | View on chart |
| LFCR | ▲ Buy | Open Market | 2,000 | $21K | 1/12/2022 | View on chart |
| LFCR | ▲ Buy | Grant | 5,398 | $53K | 10/14/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Lifecore Biomedical to be acquired by Webster Equity Partners
Lifecore Biomedical has announced it will be acquired by Webster Equity Partners in a deal valued at up to $663.7 million. Shareholders may receive up to $9.67 per common equivalent, combining cash and contingent value rights based on performance milestones. This transaction is significant as it represents a full exit for the company, with the potential payout exceeding the current average analyst target of $6.75.
Lifecore Biomedical to be acquired by Webster Equity Partners. Lifecore Biomedical has announced it will be acquired by Webster Equity Partners in a deal valued at up to $663.7 million. Shareholders may receive up to $9.67 per common equivalent, combining cash and contingent value rights based on performance milestones. This transaction is significant as it represents a full exit for the company, with the potential payout exceeding the current average analyst target of $6.75.